Tuberculosis Diagnostics Test Market Analysis
The market by test type is categorized into radiographic method, diagnostic laboratory methods, molecular diagnostics, detection of latent infection, cytokine detection assay, detection of drug resistance (DST), phage assay, and other test types. The diagnostic laboratory methods segment is further bifurcated into microscopy, culture-based techniques, and serological tests. This segment garnered USD 836 million revenue size in the year 2023.
- This growth can be attributed to the reliability and comprehensive nature of diagnostic laboratory methods in tuberculosis testing. Diagnostic laboratory methods, incorporating sophisticated techniques such as microscopy, and culture-based methods, offer highly accurate and detailed results, contributing to a more precise diagnosis of tuberculosis.
- Additionally, smear microscopy, a fundamental and widely used tuberculosis diagnostic method, contributing to the growth of diagnostic laboratory methods segment.
- Thus, this underscores the significance of diagnostic laboratories in providing effective and reliable tuberculosis testing solutions, solidifying their dominance in the market.
Based on end-use, the tuberculosis diagnostics test market unfolds its segmentation, encompassing the domains of pathological laboratories, point of care testing (POCT), and other end users. The pathological laboratories segment garnered USD 1.20 billion revenue size in the year 2023.
- The segment’s supremacy is attributed due to their crucial role in conducting sophisticated diagnostic tests, including Nucleic Acid Amplification Tests (NAATs), molecular assays and other pathological screening.
- These laboratories ensure precision through stringent quality control measures, offering widespread accessibility and convenience.
- Thus, as centralized hubs for diagnostic services, they play a vital role in delivering accurate and timely tuberculosis diagnostic solutions.
U.S. tuberculosis diagnostics test market accounted for USD 846 million revenue size in 2023 and is predicted to witness substantial market growth over the analysis timeline.
- The dominance of the U.S. in the market is attributed to the country's advanced healthcare infrastructure, a robust research and development landscape, and a high prevalence of TB.
- For instance, in 2022, there was a second consecutive annual increase in the reported cases of tuberculosis (TB) in the U.S., according to the Centers for Disease Control and Prevention (CDC). The reported cases reached 8,300, with an incidence rate of 2.5 cases per 100,000 people.
- Thus, as the incidence of TB rises, there is a growing demand for effective diagnostic solutions, thereby stimulating market growth in the region.
- Furthermore, the region's proactive approach to adopting emerging technologies, coupled with the presence of key industry players and collaborations between academia and the healthcare sector, continues to propel market expansion in the region.